Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “European Huntington’s Disease Network (EHDN) plenary meeting 2018”
Lund Sweden, September 13, 2018 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that initial data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented by Global Coordinating Principal Investigator, Dr Ralf Railmann at the scientific conference “European Huntington’s Disease Network (EHDN) plenary meeting 2018” held September 14-16 in Vienna. The results will be presented at an oral session on September 16 and as a poster titled “LEGATO-HD Study: A phase 2 study assessing the efficacy and safety of laquinimod as a treatment for Huntington disease”. Data presented includes results on primary and secondary endpoints and safety profile. Full analysis of the study is ongoing and further results will be presented at upcoming scientific meetings.